Why are you developing a monovalent meningococcal A vaccine and not a bivalent A/C or a trivalent A/C/W135 vaccine?

Group A meningococci are dominant in Africa where they have a long history of causing massive epidemics. Enhanced bacteriologic surveillance conducted in 2003–2008 for instance, showed that over 80% of meningococcal isolates were group A. By comparison, group W135 is relatively new, and W135 epidemics have been geographically restricted to one country (Burkina Faso, in 2002), with isolate cases occurring in other meningitis belt countries.

• MVP and its advisory groups in Africa have prioritized maximum public health benefit within the shortest timeline and at the lowest cost. With that in mind, they have decided to develop a vaccine that will fight the one group that is responsible for most meningococcal cases in Africa—group A. African public health officials also feel that at a cost of 40 cents a dose, the new vaccine can be easily integrated into existing vaccine budgets.

Developing a monovalent vaccine also makes it possible to plan for vaccine introduction as early as in 2009 ...

I cant really gove you an answer,but what I can give you is a way to a solution, that is you have to find the anglde that you relate to or peaks your interest. A good paper is one that people get drawn into because it reaches them ln some way.As for me WW11 to me, I think of the holocaust and the effect it had on the survivors, their families and those who stood by and did nothing until it was too late.